正在加载视频...

视频加载失败

Most people write off the rumors around CERN immediately… But every once in a while, something comes up that makes you pause. Not because it proves anything — but because it raises just enough questions to take a second look. And that’s where things start to get interesting. Kurt Metzger

35,844 次观看 • 5 个月前 •via X (Twitter)

0 条评论

暂无评论

原始帖子的评论将显示在这里

相关视频

Joe Mazzulla refuses to call himself a championship head coach, because he doesn’t want his identity to be attached to outcomes “I’m not a championship head coach. I’m just a guy that won a championship with a bunch of other people. It comes back to the identity piece. You start walking around saying… Oh, I’m a championship head coach.’ There’s coaches who are better than I am who may have never even gotten to the playoffs. You can’t start looking at success because of that.” “In your wording is the most important thing. I’m just a guy that won a championship with a group of people. We did it together. My identity cannot be wrapped up in that…Or else, you’re just a failure for the rest of your life because you may only get one.” “If you coach for 20 and you go one out of 20… Did you have one successful year and 19 unsuccessful ones? What does that look like? The first test is being very specific about the story you tell yourself and the words that you use.” “Knowing that, I didn’t do anything. There’s a group of us that did this. And then it’s over. When you are fortunate enough to win… It tests your willpower. How are we going after more? After the first one, you’re kind of like in purgatory.” “You now have a sense of what it’s like… But you might not get back. It may take one year. It may take 10. You just don’t know.” “It tests… Are you in it for the right reasons? Because it may never come back around. But you still got to show up every day.”

Josh Chambers

22,526 次观看 • 1 个月前

$ABCL CEO Carl Hansen explains the net negative overall value creation in biotech and how AbCellera plans to beat it: “I really think it can be beat because there’s a lot of mistakes that get made in where you allocate capital.” “If you’re a biotech and you start a company on a drug, and you go public and have a drug, and now the data is looking not that great, you just keep running that drug. … Because if you quit that drug, the company is done.” “So, because you’re so concentrated on one thing, you end up having blinders. It’s like a cult of a molecule. And even a real, practical, capital access problem that makes you continue to move things forward” ______________________________________ “Another problem is that many of the drugs that get started, get started by people who don’t understand the competitive or commercial landscape and have no intent of ever actually manufacturing it. … Because they know someone else is going to buy it. So then their framework is not ‘Am I making a drug that’s going to make a difference for people?’ The framework is ‘Can I make something that I think someone will take off my hands?’ And that happens a lot.” “There are many acquisitions where a big pharma company spends $10B, $20B, and it’s a complete bust. So really no value is generated for patients but someone was able to get a good exit on that because they anticipated what someone would want. And a lot of decision making gets done like that”. _______________________________________ “I’m not saying that we have this all solved. But what we’re trying to do is create a framework where we are able to take many bets so that we don’t fall in love with anything, or we don’t have to fall in love with anything. … And then always hold up very explicitly what we know and what we don’t know along the dimensions that matter. The dimensions that matter are - Will it work? That’s a science. - When it gets where will people care? - Is it differentiated? - Does it solve a big problem? In order to get it there, is there a path with our resources and expertise that would allow us to see it through?” “When you start to hold things up like that, you start to see where the mistakes are, where the uncertainties are, and you can be more rational in deciding ‘We’re going to run it to here because we get to flip the card and if the card goes the wrong way we’re going to kill it because we’ve got something else behind it.’” “I do think that if done right, and if you can pick the right opportunities, the success rate can be well higher than an order of magnitude better. … And there are examples of this… companies I’ve mentioned, you know, Regeneron, their success rate is at least 10x the industry in bringing programs forward and getting them approved. … So it’s… you can do it better that way”

Jack Prescott

31,665 次观看 • 2 个月前